was performed by Kaplan-Meier curves and Log-Rank test.Statistical significance was considered for values of p <0.05.Results: PET CT images of 78 patients were centrally reviewed. All patients are currently alive (OS=100%). After a median follow-up of 60 months (range 17-139) 17 patients (21%) had disease recurrence, with RFS of 60% at 104 months (median not reached). The median time to relapse was 8 months (range 3-39). Splenic involvement, anemia (Hb<12 gr/dl) and bulky disease at diagnosis increased risk of relapse. Patients with EoT DS1 (56 cases) showed 83% RFS at 100 months (median not reached). Median RFS worsened for higher DS: 77 months for DS2 (12 cases), 2 months for DS3 (2 cases), 26 months for DS 4 (3 cases), and 14 months for DS5 (p <0.001) [Shown in figure]. There was a longer time frame to relapse in DS1/2 compared to DS≥3 (median time of 34 and 4 months respectively). Comparing I-
Background: Autoimmune neutropenia (AIN) is common form of neutropenia in children. AIN presents with absolute neutrophil count (ANC) of less than 0.5 x 10 9 /L, but mild infection and spontaneous resolution. AIN is caused by anti-neutrophil antibodies (ANA). Detection of ANA is usually helpful in the diagnosis of AIN, but is controversy about the exclusion of congenital neutropenia or the prediction of outcome. Aims: The purpose of this study was to demonstrate the efficacy of the ANA testing for predicting clinical outcomes and spontaneous resolution of neutropenia in children with neutropenia. Methods: We reviewed the records of 62 patients with neutropenia of less than 1.5 x 10 9 /L who were tested for ANA (positive or negative) in
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.